# A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

> **NCT07223021** · PHASE3 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 130 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** CAR-T

## Key facts

- **NCT ID:** NCT07223021
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-20
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223021, "A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07223021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*